Drugs / MDG1011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03503968 | Mar 2018 → Jun 2022 | — | MediGene | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDG1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03503968 ↗ |
| Modality | Cell therapy | “This is a multicentre, non-randomized, open-label, Phase I/II clinical trial of MDG1011, an investigational medicinal product (IMP), consisting of patient-derived autologous T...” NCT03503968 ↗ |
| Route | Intravenous | “treated with a single intravenous (i.v.) infusion of IMP” NCT03503968 ↗ |
| Target | PRAME | “It is specific for the target antigen PReferentially expressed Antigen in MElanoma (PRAME).” PMID 39858024 ↗ Jan 2025 |